The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): A systematic review and meta-analysis

36Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer treatment. Methods: We examined data from PubMed, Web of Science, EBSCO, and Cochrane Library. Eleven articles fulfilled our criteria, which we divided into 3 groups: Nivolumab plus ipilimumab versus nivolumab (the dose used for monotherapy is 3 mg/kg), nivolumab plus ipilimumab versus ipilimumab (the dose used for monotherapy is 3 mg/kg), and nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (N1I3) versus nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (N3I1). We measured the complete response (CR), partial response (PR), objective response rate (ORR), and TRAEs in any grade and grade 3 or higher. Results: The overall effect estimate favored the combined immunotherapy group in terms of the ORR (RR: 1.40, p < 0.001) and PR (RR: 1.50, p < 0.001) than nivolumab alone. Compared with ipilimumab alone, the combined immunotherapy group had better CR (RR: 4.89, p < 0.001), PR (RR: 2.75, p < 0.001), and ORR (RR: 3.31, p < 0.001). Finally, N1I3 showed better PR (RR: 1.35, p = 0.006) and ORR (RR: 1.21, p = 0.03) than N3I1. The incidence of any TRAEs was similar between both groups (RR: 1.05, p = 0.06). However, the incidence of serious adverse events (grade 3 or higher) was lower in group N3I1 than group N1I3 (RR: 1.51, p < 0.001). Conclusion: This meta-analysis showed that the curative effect of nivolumab plus ipilimumab was better than that of nivolumab or ipilimumab monotherapy. In the combined immunotherapy group, N1I3 was more effective than N3I1. Although the side effects were slightly increased in N1I3 group, overall safety was acceptable.

References Powered by Scopus

CTLA-4 control over Foxp3<sup>+</sup> regulatory T cell function

2442Citations
N/AReaders
Get full text

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

2389Citations
N/AReaders
Get full text

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial

2307Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

116Citations
N/AReaders
Get full text

Chronic inflammation, cancer development and immunotherapy

75Citations
N/AReaders
Get full text

Gastric cancer and genomics: review of literature

37Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chen, J., Li, S., Yao, Q., Du, N., Fu, X., Lou, Y., … Tang, Y. (2020, July 3). The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): A systematic review and meta-analysis. World Journal of Surgical Oncology. BioMed Central. https://doi.org/10.1186/s12957-020-01933-5

Readers over time

‘20‘21‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

50%

Researcher 7

44%

Lecturer / Post doc 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

76%

Immunology and Microbiology 2

12%

Pharmacology, Toxicology and Pharmaceut... 1

6%

Chemistry 1

6%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free
0